Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Arcadia Biosciences's EBITDA for the
three
months ended in Mar. 2026 was €-0.67 Mil. Arcadia Biosciences's Revenue for the
three
months ended in Mar. 2026 was €0.95 Mil. Therefore, Arcadia Biosciences's EBITDA margin for the quarter that ended in Mar. 2026 was -70.14%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Arcadia Biosciences EBITDA Margin % Related Terms
Arcadia Biosciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Arcadia Biosciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:17D vs ORISF, ARRT, CIMG: EBITDA Margin % Comparison
For the Packaged Foods subindustry, Arcadia Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcadia Biosciences EBITDA Margin % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Arcadia Biosciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Arcadia Biosciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcadia Biosciences (FRA:17D) has a EBITDA Margin % of -70.14% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Arcadia Biosciences and its competitors. According to the industry distribution chart, Arcadia Biosciences ranks #1917 out of 1957 companies in the Consumer Packaged Goods industry, placing it in the top 98%.
Is Arcadia Biosciences' EBITDA Margin % too high?
Arcadia Biosciences' current EBITDA Margin % is -70.14%. Based on the distribution chart, Arcadia Biosciences ranks #1917 out of 1957 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Arcadia Biosciences has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Arcadia Biosciences' EBITDA Margin % compare to ORISF and ARRT?
According to the Consumer Packaged Goods industry distribution chart, Arcadia Biosciences ranks #1917 out of 1957 companies for EBITDA Margin %. This places Arcadia Biosciences in the lower half of its industry. The industry median EBITDA Margin % is 9.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Consumer Packaged Goods company?
The median EBITDA Margin % among Consumer Packaged Goods companies is 9.00, based on 1,957 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Arcadia Biosciences and its competitors. For the Consumer Packaged Goods industry, the median EBITDA Margin % is 9.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcadia Biosciences's current EBITDA Margin % is -70.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcadia Biosciences stock overvalued right now?
Arcadia Biosciences (FRA:17D) has a current EBITDA Margin % of -70.14%. The stock's GF Value™ is €15.09, compared to a current price of €3.72 — trading 75.3% below its estimated fair value. The current EBITDA Margin % is -70.14%. Arcadia Biosciences' overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Arcadia Biosciences (FRA:17D), the current EBITDA Margin % is -70.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcadia Biosciences (FRA:17D) Overvalued in 2026?
Based on GuruFocus' analysis, Arcadia Biosciences stock appears to be undervalued.
The current stock price of €3.72 is trading 75.3% below its estimated GF Value™ of €15.09.
Key valuation signals for FRA:17D:
EBITDA Margin %: -70.14%
GF Value™: €15.09 vs. price of €3.72 (75.3% below fair value)
No single metric tells the full story. See the FRA:17D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcadia Biosciences Inc is a company with science-based approaches to develop high value products and drive innovation in the consumer goods industry. The company has one operating and reportable segment, which derives revenue from the sale of Zola coconut water. The company's consumer brands in the food, beverage, and body care categories, and others. Its products include: Zola Coconut Water, and Agronomic Wheat Traits. Geographically, the company operates in United States, Argentina, India, and Canada. It derives maximum revenue from United States.
43GF Score
Get the complete analysis for FRA:17D
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:17D has been successfully added to your 
